Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Foghorn Therapeutics (FHTX) Research & Development (2020 - 2025)

Foghorn Therapeutics (FHTX) has 6 years of Research & Development data on record, last reported at $20.0 million in Q3 2025.

  • For Q3 2025, Research & Development fell 18.98% year-over-year to $20.0 million; the TTM value through Sep 2025 reached $86.8 million, down 11.61%, while the annual FY2025 figure was $85.5 million, 9.59% down from the prior year.
  • Research & Development reached $20.0 million in Q3 2025 per FHTX's latest filing, down from $21.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $30.0 million in Q1 2023 and bottomed at $18.6 million in Q2 2021.
  • Average Research & Development over 5 years is $24.0 million, with a median of $24.4 million recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 62.79% in 2021, then fell 18.98% in 2025.
  • A 5-year view of Research & Development shows it stood at $22.5 million in 2021, then grew by 25.58% to $28.2 million in 2022, then decreased by 14.19% to $24.2 million in 2023, then fell by 15.27% to $20.5 million in 2024, then dropped by 2.47% to $20.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $20.0 million in Q3 2025, $21.6 million in Q1 2025, and $20.5 million in Q4 2024.